FFS it is not Season's Greetings but Happy Christmas. Please do not wind me up with any more Godless messages. Thanks to Jim for flagging up what should be a parody, but sadly is not, Neil Woodford's next business venmture. The I look at Bidstack (BIDS), NMC Health (NMC) and Circassia (CIR), two of which are surely good bets for bankruptcy in 2020.
All will be revealed soon. Meanwhile I discuss Eddie Stobart (ESL), Circassia (CIR), Thomas Cook (TCG), Amur Minerals (AMC), Neil Woodford and Watchstone Group (WTG), Quindell as was.
Oh dear! It appears from a TR-1 released by Circassia Pharmaceuticals (CIR) today as though IP Group (IPO) - a Woodford investee - has been selling shares in Circassia, a favourite of Neil Woodford...
Fully-listed IP Group (IPO) is an investment company which throws money at early-stage companies. At the last count (28 Feb 2019) Woodford’s Equity Income Fund (EIF) was 3% invested. The remit sounds fairly close to that of WPCT – and many companies are indeed the same, as pointed out in previous ShareProphets articles.
In today's bearcast I have a hot rumour about Neil Woodford and I look at a moron called Craig who owns shares in Independent Oil & Gas (IOG) and is a classic moron. I look at that company at Circassia (CIR) - a Woodford dog - and at Gear4Music (G4M). Tomorrow I take my family and my son Joshua's godfather Lucian Miers to the London Stadium to see mighty West Ham in the cup so I'm not sure when Saturday copy will arrive.
I have been taking a look through the FCA table of registered short positions, following my piece on Interserve of Friday. I don’t offer anything exhaustive, but the largest individual short positions interested me as they are as high as 5.42% of the capital. That’s quite a bet. Oh, and just as it happens, Neil Woodford features with two of them. They are also all stocks where we at ShareProphets have been bearish.
If you read the bent, freebie is our middle name, personal financie columnists in the deadwood press, fund manager Neil Woodford walks on water. I disagree and have noted before, that, maybe, after three dismal years, others are starting to see the light. But, with assistance from a leading broker, how about we have a real look at the Woodford Patient Capital Trust (WPCT) but also at the sort of dogs Neil ifalls in love with.
I am back in from the fields where I have been labouring in 40 degree plus heat. Today I offer a few thoughts on Circassia (CIR) and the risks folks just dont seem to appreciate of a) biotech and b) backing stock selections of star fund managers, in this case Neil Woodford - who incidentally is clearly a very talented chap. I look at Gulf Keystone (GKP), XCite Energy (XEL), China Frauds and then in some detail at Blur (BLUR). For further info on its brain dead dickhead of a PR man Dominic Barretto go HERE
Hats off to veteran journalist Tim Blackstone who called Circassia (CIR) as a short with a £900 million market cap on January 16 this year HERE. Today the shares have crashed by 64% to 98.5p giving it a market cap of just £261 million. Tim Blackstone dared to go up against Neil Woodford with this call as he is the largest shareholder. It looks like another biotech disaster for Woodie.
In the mid nineties the flagship of UK biotech was British Biotech a constituent of the FTSE 100 share index with a valuation of £1.5 billion. The company enjoyed the support of the leading healthcare analyst, Dr Ian White, and rode high on a supposed inhibitor for cancer called marimastat. In my swansong as a financial journalist I wrote a devastating critique in the Mail on Sunday in the summer of 1996 with on the record quotes from leading oncologists in Edinburgh and London. Subsequent investigations on both sides of the Atlantic found that the company “had wilfully misled the public about the progress of marimastat”. British Biotech collapsed.
Two no-one-is-watching o’clock RNSs caught my eye last night, both after 6pm when everyone had gone home for the weekend, or perhaps were limbering up for the opening skirmishes of the Rugby World Cup. One from fully-listed Circassia Pharmaceuticals plc (CIR), and the other involved the much covered AIM-listed Plus 500 (PLUS) and its proposed takeover by fully listed Playtech (PTEC).
Circassia Pharma (CIR) may not be a company name most are familiar with, but at least from a technical perspective its shares have had an overall constructive setup over recent months. I now provide an upside share price target.